Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
MabVax Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01141491
First received: June 9, 2010
Last updated: July 26, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2017
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)